Emerging Vision, Inc. (fka ISEE)

[swampboots]

ISEE true market cap rose from 40 million to almost 140 million, but the drugs for the wet version by Lucentis garner over a billion in revenues and only 15% of macular degeneration population, as opposed to this DRY version application comprising 90% of that population. And from my observations with limited parties as a non-medical person, the endpoint bar is very low for this unmet remedy for this nasty disease.
Inveric just have to peddle this statistical significance into final approval or merge with their betters to endure eons of royalties.
I see more kisses after some conferences shinning lights and media momentum.